DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and oncology support products, announced today it has a completed a series of agreements with a number of specialty pharmacy providers, leading group purchasing organizations (GPOs), retail partners, reimbursement experts, and an industry-leading third-party logistics provider. DARA believes these agreements provide the company comprehensive commercial coverage across the national oncology market.
As part of an integrated national network with annual sales of over $1 billion in cancer therapeutics, DARA has significantly enhanced its commercial scale and capabilities. Its distribution network now consists of more than 45,000 retail pharmacies, mail order pharmacies, and long-term care facilities. This network provides DARA with established reimbursement and logistics expertise, with more than 300 sales and marketing personnel uniquely focused on oncology and oncology support products, and further provides the company with additional partnering opportunities.
DARA’s vertically integrated platform is headed by a team of five U.S. regional business directors who will coordinate and execute the commercialization of DARA’s growing suite of products. Each director has more than 20 years of commercial experience, as well as extensive expertise in product launches and niche product marketing.
“Our goal is to become a leading oncology and oncology supportive care company in the United States,” said David J. Drutz, MD, DARA’s chief executive officer. “These partnerships represent an important step toward that goal. The relationships we’ve developed across commercial players provide benefits to DARA, healthcare providers, patients, and caregivers alike. We have a broad platform from which to educate people about our products and their value. Through our specialty pharmaceutical relationships, we have the ability to create a strong presence in all oncology market segments. We provide flexibility to patients who receive prescription medicine through mail order or retail pharmacies, as well as make available to them financial support. Most importantly we are establishing DARA as a long-term, committed player in oncology and oncology supportive care.”